Loading…
CalciMedica, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -91.3% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 3 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Year-end price | $32.95 | $17.70 | $14.30 | |
| P/B | — | — | 16.6x | 10.1x |
| EPS | -$1.97 | -$1.22 | -$7.66 | |
| ROE | — | — | -95.07% | -421.20% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| UPCUniverse Pharmaceuticals INC | $4.90 | — | 0.0x | — | -3.50% | $3.25M |
| PPCBPropanc Biopharma, Inc. | $1.35 | 0.0x | 0.1x | — | -126.98% | $3.08M |
| TNONTenon Medical, Inc. | $5.00 | — | — | — | -551.19% | $3.34M |
| GNPXGenprex, Inc. | $3.67 |
CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. The company also develops Auxora for the treatment of ulcerative colitis, traumatic brain injury, and allergic asthma; and oral CRAC channel inhibitors for use in chronic inflammatory and immunologic disease. The company is based in La Jolla, California.
Company description provided by Yahoo Finance.
| 0.1x |
| 0.1x |
| — |
| -203.86% |
| $3.01M |
| CLDICalidi Biotherapeutics, Inc. | $1.32 | — | 0.9x | — | -672.22% | $3.41M |
| MEDSDataMeds AI, Inc. | $0.96 | — | — | — | — | $2.94M |